New therapies to treat niche populations will drive Parkinson's market

15 October 2014

The Parkinson’s disease (PD) pharmacotherapy market will grow 5% annually from $2.3 billion in 2013 to $3.8 billion in 2023, new research finds.

This growth will be fueled by the launch of several emerging therapies - including new molecular entities in established drug classes, reformulations of time-tested products, and novel first-in-class entrants that target a range of clinically-important subpopulations facing diverse unmet needs, according to a new report from Decision Resources Group.

Other key findings from the Pharmacor report, titled Parkinson’s Disease, include:

Improved rescue therapies: Interviewed experts show enthusiasm for Civitas Therapeutics’ CVT-301 as an effective, patient-friendly alternative to injectable formulations of apomorphine for PD patients experiencing “off” episodes. Decision Resources forecasts CVT-301 will earn around $700 million in the US market in 2023 with the potential for additional revenues through a global launch, prospects which appear stronger following Acorda Therapeutics’ September 2014 announcement to acquire Civitas (The Pharma Letter September 24).
First approval for PD-associated psychosis: Acadia Pharmaceuticals’ (Nasdaq: ACAD) Nuplazid (pimavanserin) is poised to become the first therapy approved specifically to treat PD-associated psychosis, a key co-morbidity that is undertreated and underserved by current off-label options, which can exacerbate motor symptoms. Following a projected US and European launch beginning in 2016, DR forecasts Nuplazid will increase the number of patients receiving an antipsychotic for PD-associated psychosis and garner PD sales of about $400 million in 2023.
Reformulations of levodopa: Although levodopa remains the patient share leader in PD, the pharmacokinetic shortcomings of marketed levodopa products leave interviewed experts open to additional reformulations. However, based on available data, it remains unclear whether emerging brands such as Impax Laboratories’ (Nasdaq: IPXL) Rytary (carbidopa and levodopa) will deliver a clinically-meaningful advance for patients needing levodopa, which has been generically available for many years.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK